Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

recruiting375%
active_not_recruiting125%

Recent Activity

4 active trials
Showing 4 of 4
recruitingphase_2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

NCT06961084
recruitingphase_1

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NCT07145177
active_not_recruitingphase_1

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

NCT05245006
recruitingphase_1

Imaging of Solid Tumors Using 18F-TRX

NCT06942104

Clinical Trials (4)

Showing 4 of 4 trials
NCT06961084Phase 2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Recruiting
NCT07145177Phase 1

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Recruiting
NCT05245006Phase 1

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Active Not Recruiting
NCT06942104Phase 1

Imaging of Solid Tumors Using 18F-TRX

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4